MedDevice formerly MLAB ymb
MedDevice formerly MLAB19 minutes ago
Dear Longs and BOD at CYDY,
I appreciate the chatter about GSK and other Big Pharma interest in Leronlimab. The interest is long over due by Big Pharma, but let us not lose site of Leronlimab's market potential. Any non-revenue company negotiates from a position of potential. We have no revenue track record. We have leverage, if there are more than one interested player. IMHO I believe we have more than one. I have been fortunate to be close enough to these type of negotiations in my past ( I was feeding market information into our negotiation team members). We had no revenue but had developed a novel medical device that had potential to treat different arrhythmias.
In CYDY's case, Leronimab has multiple indications in which we have evidence of strong potential. Market info is from (synthesis 1 2021 Seeking Alpha)
1) HIV monotherapy and combination therapy is $14 billion market size just in the U.S.
2) Conservative estimates on Long Covid are $324 billion. Just 10% of that and it is $32 billion
3) Breast cancer alone in 2019 was $21.58 billion
4) The global solid tumor market in 2018 was $121.3 billion
5) NASH by 2029 is projected to be $84.3 billion
We have so many more indications that Leronlimab has potential to address, but just look at the above indications: HIV, Long Covid, Breast cancer, Solid tumor and NASH total addressable market size and it is = $565.18 billion. Just getting 10% of that is $56 billion. THERE IS NO WAY we should ever accept $10 per share.
Remember that SK stated that Leronlimab could be like Abbvie's HUMIRA and HUMIRA earned approximately $20.7 billion last year.
I believe that Ms. Urbach and Dr. Arman and other CYDY officers on the negotiation team, will not be using historical buyout numbers, because that is extremely limiting. However, I would expect GSK and the other Pharma players to use a historical approach. Thats how these things start out and eventually both sides start to move a lot closer or a little closer. We'll know when things are announced.
I do not know if we will be in a partnership or a buyout. If it is a buyout, it better be significantly more than $10 per share. You know how some posters say "know what you own"; I say know what it's worth and CYDY is worth a ton more than $10 per share.
CYDY management put out the call for 350 million more shares by August 31. IMHO that was a calculated move to set a psuedo-deadline on discussions. If it is a buyout before August 31, the price is X times 1 billion shares or after August 31 it is X times 1.35 billion shares.
"Aim high" my fellow longs!